![]() |
Name |
2-(21-Amino-3,20-dihydroxydocosan-2-yl)oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
Molecular Formula | C28H57NO8 | |
IUPAC Name* |
2-(21-amino-3,20-dihydroxydocosan-2-yl)oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
SMILES |
CC(C(CCCCCCCCCCCCCCCCC(C(C)OC1C(C(C(C(O1)CO)O)O)O)O)O)N
|
|
InChI |
InChI=1S/C28H57NO8/c1-20(29)22(31)17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-23(32)21(2)36-28-27(35)26(34)25(33)24(19-30)37-28/h20-28,30-35H,3-19,29H2,1-2H3
|
|
InChIKey |
FZSYYVOKNJZJTF-UHFFFAOYSA-N
|
|
Synonyms |
NCGC00347555-02!2-(21-amino-3,20-dihydroxydocosan-2-yl)oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
CAS | NA | |
PubChem CID | 45359385 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 535.8 | ALogp: | 4.6 |
HBD: | 7 | HBA: | 9 |
Rotatable Bonds: | 22 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 166.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 37 | QED Weighted: | 0.103 |
Caco-2 Permeability: | -5.471 | MDCK Permeability: | 0.00002670 |
Pgp-inhibitor: | 0.041 | Pgp-substrate: | 0.064 |
Human Intestinal Absorption (HIA): | 0.978 | 20% Bioavailability (F20%): | 0.908 |
30% Bioavailability (F30%): | 0.934 |
Blood-Brain-Barrier Penetration (BBB): | 0.053 | Plasma Protein Binding (PPB): | 90.50% |
Volume Distribution (VD): | 0.685 | Fu: | 4.67% |
CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.065 |
CYP2C19-inhibitor: | 0.008 | CYP2C19-substrate: | 0.052 |
CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.781 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.121 |
CYP3A4-inhibitor: | 0.025 | CYP3A4-substrate: | 0.02 |
Clearance (CL): | 2.119 | Half-life (T1/2): | 0.16 |
hERG Blockers: | 0.258 | Human Hepatotoxicity (H-HT): | 0.078 |
Drug-inuced Liver Injury (DILI): | 0.02 | AMES Toxicity: | 0.212 |
Rat Oral Acute Toxicity: | 0.048 | Maximum Recommended Daily Dose: | 0.009 |
Skin Sensitization: | 0.326 | Carcinogencity: | 0.023 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.907 |